Movement Alert｜DUALITYBIO-B Rises 5.34% in Regular Trading, ESMO Conference Approaching Amid Biotech Sector Rally

Market Focus09-29 09:56

On September 29, DUALITYBIO-B rose 5.34% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 31.30 million HKD. The gain was primarily driven by the upcoming ESMO Annual Meeting scheduled for late October in Madrid, alongside a broader rally in the biotech sector.

According to the latest disclosed conference agenda, 32 China-origin clinical studies were featured among breakthrough abstracts, accounting for over 30% of the total, with ADC pipeline presentations drawing heightened market expectations. DUALITYBIO-B's core candidate DB-1311, developed under a global collaboration with Roche's Genentech, recently presented combination data at the WCLC conference, reinforcing investor interest in its IO2.0+ADC strategy. The Genentech partnership, announced in late August, includes a 45 million USD upfront payment and potential milestone payments exceeding 1 billion USD.

Within the Biotechnology sector, AKESO led gains at 13.15%, followed by KEYMED BIO-B up 7.11%, BEONE MEDICINES up 2.76%, 3SBIO up 2.37%, and INNOVENT BIO up 0.78%, reflecting broad sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110275127?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110275127","market":"us","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.34% in Regular Trading, ESMO Conference Approaching Amid Biotech Sector Rally","media":"Market Focus","content":"<p><p>On September 29, DUALITYBIO-B rose 5.34% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 31.30 million HKD. The gain was primarily driven by the upcoming ESMO Annual Meeting scheduled for late October in Madrid, alongside a broader rally in the biotech sector.</p><p>According to the latest disclosed conference agenda, 32 China-origin clinical studies were featured among breakthrough abstracts, accounting for over 30% of the total, with ADC pipeline presentations drawing heightened market expectations. DUALITYBIO-B's core candidate DB-1311, developed under a global collaboration with Roche's Genentech, recently presented combination data at the WCLC conference, reinforcing investor interest in its IO2.0+ADC strategy. The Genentech partnership, announced in late August, includes a 45 million USD upfront payment and potential milestone payments exceeding 1 billion USD.</p><p>Within the Biotechnology sector, AKESO led gains at 13.15%, followed by KEYMED BIO-B up 7.11%, BEONE MEDICINES up 2.76%, 3SBIO up 2.37%, and INNOVENT BIO up 0.78%, reflecting broad sector strength.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.34% in Regular Trading, ESMO Conference Approaching Amid Biotech Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.34% in Regular Trading, ESMO Conference Approaching Amid Biotech Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-29 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 29, DUALITYBIO-B rose 5.34% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 31.30 million HKD. The gain was primarily driven by the upcoming ESMO Annual Meeting scheduled for late October in Madrid, alongside a broader rally in the biotech sector.</p><p>According to the latest disclosed conference agenda, 32 China-origin clinical studies were featured among breakthrough abstracts, accounting for over 30% of the total, with ADC pipeline presentations drawing heightened market expectations. DUALITYBIO-B's core candidate DB-1311, developed under a global collaboration with Roche's Genentech, recently presented combination data at the WCLC conference, reinforcing investor interest in its IO2.0+ADC strategy. The Genentech partnership, announced in late August, includes a 45 million USD upfront payment and potential milestone payments exceeding 1 billion USD.</p><p>Within the Biotechnology sector, AKESO led gains at 13.15%, followed by KEYMED BIO-B up 7.11%, BEONE MEDICINES up 2.76%, 3SBIO up 2.37%, and INNOVENT BIO up 0.78%, reflecting broad sector strength.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1110275127","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110275127","pubTimestamp":1790646983,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 29, DUALITYBIO-B rose 5.34% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 31.30 million HKD. The gain was primarily driven by the upcoming ESMO Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势警报|DUALITYBIO-B 在常规交易中上涨 5.34%，ESMO 会议临近，生物技术板块上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On September 29, DUALITYBIO-B rose 5.34% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 31.30 million HKD. The gain was primarily driven by the upcoming ESMO Annual Meeting scheduled for late October in Madrid, alongside a broader rally in the biotech sector.According to the latest disclosed conference agenda, 32 China-origin clinical studies were featured among breakthrough abstracts, accounting for over 30% of the total, with ADC pipeline presentations drawing heightened market expectations. DUALITYBIO-B's core candidate DB-1311, developed under a global collaboration with Roche's Genentech, recently presented combination data at the WCLC conference, reinforcing investor interest in its IO2.0+ADC strategy. The Genentech partnership, announced in late August, includes a 45 million USD upfront payment and potential milestone payments exceeding 1 billion USD.Within the Biotechnology sector, AKESO led gains at 13.15%, followed by KEYMED BIO-B up 7.11%, BEONE MEDICINES up 2.76%, 3SBIO up 2.37%, and INNOVENT BIO up 0.78%, reflecting broad sector strength.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110275127","isCrawlerRequest":true}